Does Avodart (Dutasteride) Affect Sleep? What the Label Says
At a glance
- Drug / dutasteride (Avodart) 0.5 mg once daily, swallowed whole [1]
- Approved use / symptomatic BPH with an enlarged prostate; hair loss is off-label [1]
- Label listing for insomnia / not among the reactions reported in 1% or more of men and more often than placebo [1]
- Half-life / about 5 weeks; about 90% of steady state by 3 months [1]
What does the Avodart label say about sleep?
The label's pooled placebo-controlled BPH trials randomized 4,325 men, 2,167 to dutasteride 0.5 mg daily and 2,158 to placebo; the men's mean age was 66. The label summarizes these trials through urinary symptom scores and adverse reactions [1]. Its table of reactions reported in at least 1% of treated men and more often than placebo lists impotence, decreased libido, ejaculation disorders and breast disorders. Insomnia is not in that table. A reaction below the 1% threshold, or one no more common than on placebo, would not appear there [1].
The label notes that the sexual reactions may persist after treatment is discontinued and that dutasteride's role in that persistence is unknown [1].
What is known about mood?
Depressed mood appears among the Avodart label's postmarketing reports. The label does not list suicidal ideation [1].
A Swedish register study followed 2.2 million men aged 50 to 90. Among the 8,774 men who started dutasteride, the hazard ratio for depression was 1.68 (95% CI 1.43 to 1.96), and it stayed constant over time. Suicide was not associated with dutasteride (HR 0.98, 95% CI 0.62 to 1.54). The study was observational and mostly involved older men treated for BPH [2].
Frequently asked questions
Does dutasteride cause insomnia?
Does dutasteride change REM or deep sleep?
Does dutasteride affect mood?
References
- U.S. National Library of Medicine, DailyMed. Avodart (dutasteride) soft gelatin capsules, Waylis Therapeutics prescribing information. Avodart (dutasteride) soft gelatin capsules, Waylis Therapeutics label
- Garcia-Argibay M, Hiyoshi A, Fall K, Montgomery S. Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide. JAMA Netw Open. 2022;5(12):e2248135. Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide